Vertex Secures Alyftrek Reimbursement in Seven More Countries
Vertex secured reimbursement for its cystic fibrosis therapy Alyftrek in seven additional countries in the third quarter, bringing coverage to 32 nations. International revenue rose 16% to $1.27 billion.
Vertex Pharmaceuticals secures reimbursement for cystic fibrosis therapy Alyftrek in seven additional countries during the third quarter, bringing total international coverage to 32 nations. Global CF performance helped lift international revenue 16% to $1.27 billion. The company raised its full-ye…